Thanks @Morgo26 . But as Bamse said, at this marketvalue, it is not interesting whether the share price is 30 or 40 NOK. Its about make it or break it. If this technology and its results which has been great in all tech legs (chem, Nac or Vacc), finally can be validated and transformed into deals/commercial partnerships PCI
Biotech will probably totally at THAT day be transformed both in value and into a key player in mentioned areas!
I get a bit distressed when people regards a presentation in mRNA or vaccination technology next week as a non event. Especially at a time where the marketvalue was crushed below 1 NOK mrd (and PCIB is a company with a pipeline which has a pivotal phase ONCOLOGY in an indication which could indicate IF product as a blockbuster).
I have not noticed before that PCIB has been shorted (Nordnet) and it seems as another marketplayer has loan agreement ,MP Pensjon (I cant find a stock release which states threshold below 5%, which could imply another short position).
With regards to the Vacc leg, the company has stated that it will be in partnership or alone. A strategic decision is on overtime. If alone, the indicated amount NOK is about peanuts in biotechs) please look at the latest cash injection event at eTheRNA). No worries!
With regards to RELEASE (the real gold in the vault) I totally agree that the covid 19 situation has brought the vast majority biotechs in oncology in every clinical phases to take different action to get enrollment get going. PCIB has taken several steps to overcome this hurdle that exist for biotechs in general. The market has made its decision and has really crushed the share price already. My personal thought is that its all about RELEASE as I reckon the share price was about NOK 40-45 the day before AZ said no go…(no real AZ euphoria at all as some says it was…) and now(all analysts and comments here states almost all value of PCIB into the RELEASE asset). But as always, couldnt agree more, be cautios in any biotech investments! Regard it as high risk as it is, look at volatility. Says it all.